Servier completes its retreat from cell therapy
The sale of remaining rights to Allogene ends acrimony between the two companies.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
A panel of two halves for multiple myeloma Car-Ts
Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.
